Sam Brusco, Associate Editor04.16.24
Xstim has earned U.S. Food and Drug Administration (FDA) premarket approval for its Xstim spine fusion stimulator.
The capacitively coupled device emits a low-energy signal to promote bone healing following spinal fusion surgery. The company said it streamlines patient therapy management with an intuitive interface and sleek design, which features a large onboard color display.
The Xstim device’s commercial availability is expected in Q2 of this year, with a largeted, phased launch plan in place.
"Bone healing following spinal fusion surgery is paramount to successful patient outcomes,” said Dr. Adam Bruggerman, MD. “The availability of non-invasive bone growth stimulation options like Xstim provides my patients with an invaluable advantage. Its sleek design ensures simple therapy management without the hassle of downloading and managing extra apps."
"Xstim, Inc. is dedicated to empowering patients and surgeons to elevate the quality of care in spinal fusion rehabilitation,” added Xstim CEO Jeremy Perkins. “The introduction of the Xstim Spine Fusion Stimulator represents the beginning of our robust pipeline of bone growth stimulation innovations. We are poised to collaborate with healthcare providers and distribution partners to enhance bone fusion outcomes and elevate patient satisfaction. This FDA approval underscores our leadership in and dedication to the bone growth stimulation market."
The capacitively coupled device emits a low-energy signal to promote bone healing following spinal fusion surgery. The company said it streamlines patient therapy management with an intuitive interface and sleek design, which features a large onboard color display.
The Xstim device’s commercial availability is expected in Q2 of this year, with a largeted, phased launch plan in place.
"Bone healing following spinal fusion surgery is paramount to successful patient outcomes,” said Dr. Adam Bruggerman, MD. “The availability of non-invasive bone growth stimulation options like Xstim provides my patients with an invaluable advantage. Its sleek design ensures simple therapy management without the hassle of downloading and managing extra apps."
"Xstim, Inc. is dedicated to empowering patients and surgeons to elevate the quality of care in spinal fusion rehabilitation,” added Xstim CEO Jeremy Perkins. “The introduction of the Xstim Spine Fusion Stimulator represents the beginning of our robust pipeline of bone growth stimulation innovations. We are poised to collaborate with healthcare providers and distribution partners to enhance bone fusion outcomes and elevate patient satisfaction. This FDA approval underscores our leadership in and dedication to the bone growth stimulation market."